All In Biotech

Drug Trial Radar · NCT03170960

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

914

Actual

Start

Sep 5, 2017

Primary completion

Feb 21, 2023

Study completion Sep 30, 2027

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
May 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Conditions

  • Urothelial Carcinoma
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer
  • Castration-resistant Prostate Cancer
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Hepatocellular Carcinoma
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Colorectal Cancer
  • Head and Neck Cancer
  • Differentiated Thyroid Cancer
  • Lower Esophageal Cancer

Interventions

  • cabozantinibDrug

    Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.

  • atezolizumabDrug

    Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

  • cabozantinibDrug

    Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

  • cabozantinibDrug

    Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: MTD/Recommended DoseTime frame: Up to Day 21
  2. Dose Expansion: ORRTime frame: Up to a maximum of 59 months

Locations

124 sites in 9 countries. Site status is shown where the registry gives one.

  • Exelixis Clinical Site #53

    Gilbert, Arizona

  • Exelixis Clinical Site #18

    Phoenix, Arizona

  • Exelixis Clinical Site #1

    Duarte, California

  • Exelixis Clinical Site #20

    La Jolla, California

  • Exelixis Clinical Site #46

    Los Angeles, California

  • Exelixis Clinical Site #51

    Newport Beach, California

  • Exelixis Clinical Site #62

    Santa Monica, California

  • Exelixis Clinical Site #21

    Stanford, California

  • Exelixis Clinical Site #34

    Denver, Colorado

  • Exelixis Clinical Site #50

    Denver, Colorado

  • Exelixis Clinical Site #42

    New Haven, Connecticut

  • Exelixis Clinical Site #48

    Washington D.C., District of Columbia

  • Exelixis Clinical Site #16

    Jacksonville, Florida

  • Exelixis Clinical Site #76

    Tampa, Florida

  • Exelixis Clinical Site #60

    Atlanta, Georgia

  • Exelixis Clinical Site #79

    Atlanta, Georgia

  • Exelixis Clinical Site #32

    Harvey, Illinois

  • Exelixis Clinical Site #23

    Fairway, Kansas

  • Exelixis Clinical Site #57

    Lexington, Kentucky

  • Exelixis Clinical Site #24

    New Orleans, Louisiana

  • Exelixis Clinical Site #10

    Boston, Massachusetts

  • Exelixis Clinical Site #3

    Detroit, Michigan

  • Exelixis Clinical Site #17

    Rochester, Minnesota

  • Exelixis Clinical Site #65

    Bolivar, Missouri

  • Exelixis Clinical Site #43

    Kansas City, Missouri

  • Exelixis Clinical Site #35

    Omaha, Nebraska

  • Exelixis Clinical Site #59

    Omaha, Nebraska

  • Exelixis Clinical Site #61

    Las Vegas, Nevada

  • Exelixis Clinical Site #38

    Camden, New Jersey

  • Exelixis Clinical Site #27

    East Brunswick, New Jersey

  • Exelixis Clinical Site #31

    New Brunswick, New Jersey

  • Exelixis Clinical Site #40

    East Setauket, New York

  • Exelixis Clinical Site #11

    New York, New York

  • Exelixis Clinical Site #37

    The Bronx, New York

  • Exelixis Clinical Site #67

    Cleveland, Ohio

  • Exelixis Clinical Site #49

    Columbus, Ohio

  • Exelixis Clinical Site #64

    Kettering, Ohio

  • Exelixis Clinical Site #71

    Oklahoma City, Oklahoma

  • Exelixis Clinical Site #6

    Oklahoma City, Oklahoma

  • Exelixis Clinical Site #102

    Portland, Oregon

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.